Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Peptide-HLA-based immunotherapeutics platforms for direct modulation of antigen-specific T cells.

Scientific reports - 28 Sept 2021

Seidel Ronald D, Merazga Zohra, Thapa Dharma Raj, Soriano Jonathan, Spaulding Emily, Vakkasoglu Ahmet S, Ruthardt Paige, Bautista Wynona, Quayle Steven N, Kiener Peter A, Low Simon, Ross John F, Cemerski Saso, Suri Anish, Almo Steven C, Chaparro Rodolfo J

Abstract excerpt

Targeted pharmacologic activation of antigen-specific (AgS) T cells may bypass limitations inherent in current T cell-based cancer therapies. We describe two immunotherapeutics platforms for selective delivery of costimulatory ligands and peptide-HLA (pHLA) to AgS T cells. We engineered and deployed on these platforms an affinity-attenuated variant of interleukin-2, which selectively expands oligoclonal and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-1 Antigen
Share to CD8-Positive T-Lymphocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HLA-A Antigens

Share to Immunotherapy

Share to Lymphocyte Activation

Share to Peptides

Share to Primary Cell Culture

Share to Protein Engineering

Source

Open in PubMed Open full text

Identifiers

PMID: 34584159
DOI: 10.1038/s41598-021-98716-z
PMCID: PMC8479091

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Peptide-HLA-based immunotherapeutics platforms for direct modulation of antigen-specific T cells.PMID 34584159Read ↗

Antigen-specific nanomedicines for the treatment of autoimmune disease: target cell types, mechanisms and outcomesSemantic proximity Read ↗

TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapySemantic proximity Read ↗

The Anticancer Potential of T Cell Receptor-Engineered T Cells.Semantic proximity Read ↗

Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes.Semantic proximity Read ↗

Combined PD-L1 and TIM-3 blockade improves the expansion of fit human CD8+ antigen-specific T cells for adoptive immunotherapySemantic proximity Read ↗

Efficacy of Anti-Cancer Immune Responses Elicited Using Tumor-Targeted IL-2 Cytokine and Its Derivatives in Combined Preclinical TherapiesSemantic proximity Read ↗

Immunotherapy: Nice to see you - evolving MHC I-peptide presentation.Semantic proximity Read ↗

Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy.Semantic proximity Read ↗

T-Cell Epitope Discovery for Therapeutic Cancer Vaccines.Semantic proximity Read ↗

Targeting peptide antigens using a multiallelic MHC I-binding system.Semantic proximity Read ↗

Targeting CAR to the Peptide-MHC Complex Reveals Distinct Signaling Compared to That of TCR in a Jurkat T Cell ModelSemantic proximity Read ↗

Altered Peptide Ligands Impact the Diversity of Polyfunctional Phenotypes in T Cell Receptor Gene-Modified T Cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.